Innate Pharma pushes PACIFIC-9 data readout to first half of 2027

Innate Pharma announced on October 27, 2026 that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously.¹ The company said the revised timing reflects the event-driven nature of the study.¹

The trial, led by AstraZeneca, is testing durvalumab in combination with monalizumab or oleclumab in patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not progressed following platinum-based chemoradiation therapy.¹ Innate confirmed that enrollment in the trial is complete.¹

Monalizumab, one of the two combination agents under study, is an anti-NKG2A antibody developed by Innate Pharma in collaboration with AstraZeneca.¹ Under the companies' arrangement, AstraZeneca obtained full oncology rights to monalizumab in October 2018 through a co-development and commercialisation agreement initiated in 2015.¹

Innate describes itself as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients.¹ Its pipeline is organized around antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates.¹ Alongside that internal program, the company is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).¹

Innate Pharma also noted broader ties across the sector, saying it has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.¹